CHENGDU, China, July 27, 2018 /PRNewswire/ -- HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Sanofi to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening, to discover novel leads which will be licensed exclusively to Sanofi. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments. Financial details were not disclosed.
"We are delighted to enter into this collaboration since it further validates the role of HitGen in the rapidly developing field of DNA-encoded chemistry. We will work closely with Sanofi scientists to generate novel leads for their research programs to address unmet medical needs," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.
About HitGen Ltd
HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China, and with facilities in the USA. HitGen has established a unique platform for drug discovery research centered around DNA encoded chemical libraries (DELs). HitGen's DELs contain more than 150 billion novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for identifying small molecule leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, and research institutes to discover and develop the novel therapeutics of the future.
For more information, please visit www.hitgen.com.
Related Links :
http://www.hitgen.com
